This article will discuss the FDA’s recent acceptance of Intercept Pharmaceuticals’s obeticholic acid (OCA) new drug application (NDA) resubmission in NASH and how OCA’s likelihood of approval compares to other drugs in late-stage development.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,